Raymond James & Associates Kymera Therapeutics, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$13.9 - $23.88 $26,243 - $45,085	1,888 Added 7.73%	26,297 $365,000
Q2 2023 Jul 25, 2023	BUY	$22.4 - $34.92 $33,107 - $51,611	1,478 Added 6.45%	24,409 $561,000
Q1 2023 Apr 14, 2023	BUY	$24.84 - $38.75 $152,766 - $238,312	6,150 Added 36.65%	22,931 $679,000
Q4 2022 Feb 08, 2023	BUY	$19.57 - $30.92 $6,203 - $9,801	317 Added 1.93%	16,781 $418,000
Q3 2022 Oct 25, 2022	BUY	$20.91 - $34.27 $344,262 - $564,221	16,464 New	16,464 $358,000

184

64.4M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.28B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.